Are the odds shifting against pharma in the fight for cheaper treatment for macular degeneration?

    loading  Checking for direct PDF access through Ovid

Abstract

Doctors plan to prescribe bevacizumab despite legal threats from drug companies, and against GMC and NICE guidance. Responses to the policy and new legal rulings hint at a turning point in a long-running battle in which £0.5bn potential NHS savings are at stake, reports Deborah Cohen

Related Topics

    loading  Loading Related Articles